Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration. 31669558 2020
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE In this study, a prodrug of EGCG (pro-EGCG) alleviated mouse laser-induced CNV leakage and reduced CNV area by down-regulating HIF-1α/VEGF/VEGFR2 pathway; M1-type macrophage/microglia polarization; as well as endothelial cell viability, proliferation, migration and tube formation, indicating a novel potential therapy for AMD. 31743875 2020
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Brolucizumab (Beovu<sup>®</sup>) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. 31768932 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Intravitreal injections of anti-vascular endothelial growth factor agents such as ranibizumab and aflibercept are the first-line treatment for neovascular age-related macular degeneration (AMD). 30842468 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Our study described the 2-year real-life outcome of anti-vascular endothelial growth factor treatment of diabetic macular edema and age-related macular degeneration. 31617403 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis. 31132283 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE An ideal drug candidate for both types of AMD is the one which offers significant protection to the retinal cells from oxidative stress and inhibit VEGF release. 31317354 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial. 30301555 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Although they share some receptor signalling pathways, many of the actions of PlGF are distinct from VEGF and this has revealed the enticing prospect that it could be a useful therapeutic target for treating early and late stages of diabetic retinopathy (DR) and neovascular age-related macular degeneration (AMD). 31055948 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE In conclusion, the presented data reveal that gene therapy targeting VEGFA via multigenic AAV vectors displays combined efficacy, suggesting that dual-acting therapy is an important tool in future eye gene therapy for the treatment of neovascular ocular diseases, including AMD. 30825671 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Here, we describe a deep sequencing-aided engineering strategy to fine-tune the specificity of an angiopoietin-2 (Ang2)/vascular endothelial growth factor (VEGF) dual action Fab, 5A12.1 for the treatment of age-related macular degeneration. 28585908 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 GeneticVariation disease BEFREE To investigate the association of treatment assignment (intravitreal aflibercept vs ranibizumab) and baseline characteristics with fellow eye conversion to nAMD in the VEGF (Vascular Endothelial Growth Factor) Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies. 31294771 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Effective therapy for AMD is currently limited to the treatment of the patient with intravitreal injections of anti-VEGF drugs. 31456444 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE This association was also found retrospectively in a larger sample of patients with neovascular AMD at 12 (ρ = 0.46; 95% CI, 0.16-0.68; P = .004), 24 (ρ = 0.49; 95% CI, 0.20-0.70; P = .002), and 36 (ρ = 0.65; 95% CI, 0.41-0.80; P < .001) months and patients with PCV at 12 (ρ = 0.27; 95% CI, -0.28 to 0.68; P = .30), 24 (ρ = 0.60; 95% CI, 0.12-0.85; P = .02), and 36 (ρ = 0.70; 95% CI, 0.27-0.90; P = .005) months, suggesting that this association is not specific to AMD but rather reflects VEGF activity in neovascularization. 30844038 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Repeated injections with anti-VEGFA (vascular endothelial growth factor A) are the only effective therapy in wet AMD. 31633290 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE The intravitreous injection of therapeutic proteins that neutralize vascular endothelial growth factor (VEGF) family members is efficient to reduce macular edema associated with wet age-related macular degeneration (AMD), retinal vein occlusion (RVO) and diabetic retinopathy (DR). 31173913 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE In December 2004, the US Food and Drug Administration approved the first aptamer-based therapeutic, pegaptanib (Macugen), targeting vascular endothelial growth factor, for the treatment of age-related macular degeneration. 31766318 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE Aqueous humor levels of vascular endothelial growth factor, soluble vascular endothelial growth factor receptor (sVEGFR)-1, sVEGFR-2, and inflammatory factors (monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, and IL-8) were significantly higher in the AMD group than in the cataract group (all p < 0.05). 30048978 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Furthermore, VEGF is involved in the development and growth of cancer and other diseases like agerelated macular degeneration, rheumatoid arthritis, diabetes mellitus, and neurodegenerative disorders. 31615077 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. 31286206 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE To characterize the natural history and response of age-related macular degeneration-associated peripapillary choroidal neovascularization to anti-vascular endothelial growth factor therapy. 30028411 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Age- and sex-matched control groups included 473 pre-anti-vascular endothelial growth factor era wet AMD patients, 504 concurrent time dry AMD patients, and 504 patients with no AMD. 30986797 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 AlteredExpression disease BEFREE We investigated how blue light affects VEGF expression and secretion using A2E-loaded retinal pigment epithelium (RPE) cells, a cell model of AMD. 31644596 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE Bevacizumab, a vascular endothelial growth factor (VEGF)-targeting drug, is widely used as an off-label therapeutic for age-related macular degeneration (AMD). 30959236 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.400 Biomarker disease BEFREE To describe the synergistic benefits and cost savings from the use of optical coherence tomography (OCT) and vascular endothelial growth factor (VEGF) inhibitors, particularly intravitreal bevacizumab, in the treatment of exudative age-related macular degeneration (AMD). 30851267 2019